Oncology Hematology West, PC dba Nebraska Cancer Specialists - Fremont, Fremont
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island, Grand Island
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional, Grand Island
at 5 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06758401

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Research Site, Lincoln

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06868277

Pan-tumor MRD Study

Cancer Partners of Nebraska, Lincoln

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06605404

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Grand Island
Research Site, Omaha

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06357533

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Omaha

Nagre-recruitPhase 2

Edad 18 hanggang 95 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT05061550

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC), Hastings

Nagre-recruitPhase 2/3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06712316

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Nebraska Hematology-Oncology /ID# 272970, Lincoln
Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527, Omaha

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06568939

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Lincoln

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06692738

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Local Institution - 007-590D, Grand Island
Local Institution - 007-590A, Omaha
Local Institution - 007-590B, Omaha
at 2 pa

Nagre-recruitPhase 2/3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04613596

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

NHO Revive Research Institute, Lincoln

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06793215

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, Lincoln

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07291037

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

Nebraska Cancer Specialists, Omaha

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 27, 2026 · NCT07660055

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

Nebraska Hematology-Oncology, Lincoln

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT07288177

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Nebraska Cancer Specialists, Omaha

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT04198766

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

University of Nebraska Medical Center, Omaha

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 27, 2026 · NCT05242965

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

Nebraska Medicine-Bellevue, Bellevue
Nebraska Medicine-Village Pointe, Omaha
University of Nebraska Medical Center, Omaha

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT06686771

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Nebraska Cancer Specialist, Grand Island

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 30, 2026 · NCT06162221

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

University of Nebraska Medical Center, Omaha

Nagre-recruitPhase 2

Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Hun 26, 2026 · NCT04614103

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399, Omaha

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT05005403

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
XCancer Omaha / Urology Cancer Center, Omaha

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Hun 11, 2026 · NCT05283330

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

USA14-0, Lincoln

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update May 22, 2026 · NCT06953089

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Research Site, Omaha

Nagre-recruitPhase 3

Edad 18 hanggang 130 · Lahat ng kasarian · Na-update May 14, 2026 · NCT06417814

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

University of Nebraska Medical Center, Omaha

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT04317534

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

CHI Health Good Samaritan, Kearney

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06418204

Repositioning Immunotherapy in VetArans With Lung Cancer

Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE, Omaha

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Mar 2, 2026 · NCT06275360

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Nebraska Cancer Specialists, Omaha

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Peb 18, 2026 · NCT07030257

GEMINI-NSCLC: NSCLC Biomarker Study

Nebraska Cancer Specialists, Omaha

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Peb 5, 2026 · NCT05236114

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Omaha

Nagre-recruitObservasyonal na pag-aaral

Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

Nebraska Cancer Specialists, Omaha

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Abr 23, 2025 · NCT06046495

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.